Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2022-05-25 17:22 Tx date 2022-05-25 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$31,350
+100 vol $313.50 each |
2,500 | |
Filed 2022-05-20 16:19 Tx date 2022-05-20 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$686.00
+200 vol $3.43 each |
2,400 | |
Filed 2022-05-19 14:49 Tx date 2022-05-19 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$363.50
+100 vol $3.63 each |
2,200 | |
Filed 2022-05-19 14:48 Tx date 2022-05-18 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$388.00
+100 vol $3.88 each |
2,100 | |
Filed 2022-05-19 14:45 Tx date 2022-05-12 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,594
+2,000 vol $3.80 each |
2,000 | |
Filed 2022-05-12 11:51 Tx date 2022-05-12 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,594
+2,000 vol $3.80 each |
||
Filed 2022-05-12 11:51 Tx date 2022-05-12 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,594
+2,000 vol $3.80 each |
2,000 | |
Filed 2022-05-12 11:51 Tx date 2022-03-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Herschkowitz, Samuel
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-05-11 14:56 Tx date 2022-05-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,260
+500 vol $4.52 each |
79,482 | |
Filed 2022-05-11 14:53 Tx date 2022-05-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$466.00
+100 vol $4.66 each |
2,506 | |
Filed 2022-05-11 14:53 Tx date 2022-05-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$453.00
+100 vol $4.53 each |
2,406 | |
Filed 2022-05-11 14:52 Tx date 2022-05-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$900.00
+200 vol $4.50 each |
2,306 | |
Filed 2022-05-11 14:52 Tx date 2022-05-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$440.00
+100 vol $4.40 each |
2,106 | |
Filed 2022-05-06 16:03 Tx date 2022-05-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-2,158,445 vol |
10,846 | |
Filed 2022-05-06 16:02 Tx date 2022-05-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-485,013 vol |
2,437 | |
Filed 2022-03-17 15:29 Tx date 2022-03-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+3,961,218 vol |
15,796,540 | |
Filed 2022-03-17 15:28 Tx date 2022-03-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-3,961,218 vol |
0 | |
Filed 2022-03-11 19:14 Tx date 2022-03-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: 7th Merchant Corp (Indirect Ownership)
|
Common Shares
97 - Other
|
+927,092 vol |
927,092 | |
Filed 2022-03-11 19:12 Tx date 2020-06-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: 7th Merchant Corp (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-03-11 19:11 Tx date 2022-03-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
|
Common Shares
97 - Other
|
-927,092 vol |
0 | |
Filed 2022-03-11 19:07 Tx date 2022-03-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: Gale Bale (Control or Direction)
|
Common Shares
97 - Other
|
-92,000 vol |
0 | |
Filed 2021-07-06 19:44 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$150,963
+3,151,639 vol $0.0479 each |
9,628,533 | |
Filed 2021-07-06 19:41 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,035,178
+21,611,238 vol $0.0479 each |
41,132,615 | |
Filed 2021-07-06 19:37 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$136,316
+2,845,855 vol $0.0479 each |
7,969,472 | |
Filed 2021-07-06 19:33 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$95,053
+1,984,407 vol $0.0479 each |
4,446,723 | |
Filed 2021-07-06 19:30 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$185,469
+3,872,013 vol $0.0479 each |
9,494,722 | |
Filed 2021-07-06 19:26 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$209,551
+4,374,775 vol $0.0479 each |
10,013,137 | |
Filed 2020-12-18 07:37 Tx date 2020-12-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,569,291 vol |
2,169,291 | |
Filed 2020-12-18 07:34 Tx date 2020-12-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+3,961,218 vol |
3,961,218 | |
Filed 2020-12-18 07:32 Tx date 2018-05-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 07:29 Tx date 2020-12-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,569,291 vol |
1,569,291 | |
Filed 2020-12-18 07:28 Tx date 2020-06-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 07:25 Tx date 2020-12-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Cotton, Geoffrey David
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,569,291 vol |
1,569,291 | |
Filed 2020-12-18 07:24 Tx date 2020-05-04 |
$ASP
Acerus Pharmaceuticals Corporation |
Cotton, Geoffrey David
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 07:14 Tx date 2020-12-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,143,218 vol |
2,462,316 | |
Filed 2020-12-18 07:08 Tx date 2020-12-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,569,291 vol |
4,484,463 | |
Filed 2020-12-04 13:37 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
|
Common Shares
99 - Correction of information
|
$7,937
+317,514 vol $0.025 each |
927,092 | |
Filed 2020-12-04 13:33 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$46,784
+1,871,380 vol $0.025 each |
5,464,133 | |
Filed 2020-11-27 13:34 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$57,309
+2,292,371 vol $0.025 each |
||
Filed 2020-11-30 10:41 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$3,435
+137,431 vol $0.025 each |
401,278 | |
Filed 2020-11-27 13:41 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$12,734,214
+509,368,574 vol $0.025 each |
1,376,502,750 | |
Filed 2020-11-27 13:38 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$78,133
+3,125,327 vol $0.025 each |
4,551,727 | |
Filed 2020-11-27 13:34 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$57,309
+2,292,371 vol $0.025 each |
5,885,124 | |
Filed 2020-11-27 13:31 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$748.75
+29,950 vol $0.025 each |
487,450 | |
Filed 2020-11-27 13:18 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$614.63
+24,585 vol $0.025 each |
71,785 | |
Filed 2020-11-27 13:06 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$34,090
+1,363,616 vol $0.025 each |
11,835,322 | |
Filed 2020-11-16 10:24 Tx date 2020-11-13 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,000
+400,000 vol $0.03 each |
457,500 | |
Filed 2020-09-14 14:34 Tx date 2020-09-09 |
$ASP
Acerus Pharmaceuticals Corporation |
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$68,593
+1,319,098 vol $0.052 each |
1,319,098 | |
Filed 2020-09-14 14:31 Tx date 2020-09-08 |
$ASP
Acerus Pharmaceuticals Corporation |
Hickey, Kevin Thomas
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-08-17 16:49 Tx date 2020-08-12 |
$ASP
Acerus Pharmaceuticals Corporation |
Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$303,830
+5,123,617 vol $0.0593 each |
5,123,617 | |
Filed 2020-08-17 16:47 Tx date 2020-08-03 |
$ASP
Acerus Pharmaceuticals Corporation |
Sorli, Christopher Hutchins
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-06-28 18:41 Tx date 2020-06-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: Gale Bale (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
92,000 | ||
Filed 2020-06-28 18:41 Tx date 2020-06-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: Elizabeth Carlson (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
106,657 | ||
Filed 2020-06-28 18:40 Tx date 2020-06-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Holder: 1680897 Ontario (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
609,578 | ||
Filed 2020-06-28 18:39 Tx date 2020-06-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Leckie, William Scott
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
3,592,753 | ||
Filed 2020-04-02 18:07 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$187,490
+4,148,017 vol $0.0452 each |
5,622,709 | |
Filed 2020-04-02 18:03 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$235,452
+5,209,137 vol $0.0452 each |
5,638,362 | |
Filed 2020-04-02 17:59 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$837,166
+18,521,377 vol $0.0452 each |
19,521,377 | |
Filed 2020-04-02 17:56 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$104,645
+2,315,172 vol $0.0452 each |
2,715,172 | |
Filed 2020-04-02 17:42 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$104,645
+2,315,172 vol $0.0452 each |
2,915,172 | |
Filed 2020-04-02 17:38 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$104,645
+2,315,172 vol $0.0452 each |
2,915,172 | |
Filed 2020-04-02 17:33 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
$104,645
+2,315,172 vol $0.0452 each |
2,940,172 | |
Filed 2020-04-02 17:16 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$244,173
+5,402,068 vol $0.0452 each |
6,476,894 | |
Filed 2020-03-11 11:53 Tx date 2020-03-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
600,000 | |
Filed 2020-02-21 17:04 Tx date 2020-02-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+749,230,776 vol |
867,134,176 | |
Filed 2019-12-13 14:18 Tx date 2019-03-10 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
625,000 | |
Filed 2019-12-13 14:16 Tx date 2018-04-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
450,000 | |
Filed 2019-12-13 14:15 Tx date 2017-03-12 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
375,000 | |
Filed 2019-12-13 14:14 Tx date 2016-07-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
200,000 | |
Filed 2019-12-12 10:24 Tx date 2019-03-10 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
625,000 | |
Filed 2019-12-12 10:22 Tx date 2018-11-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
52 - Expiration of options
|
-25,000 vol |
450,000 | |
Filed 2019-11-04 10:38 Tx date 2019-11-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,600
+20,000 vol $0.08 each |
61,000 | |
Filed 2019-11-04 10:38 Tx date 2019-10-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$85.00
+1,000 vol $0.085 each |
41,000 | |
Filed 2019-10-17 15:53 Tx date 2019-10-17 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,350
+130,000 vol $0.095 each |
10,471,706 | |
Filed 2019-08-12 10:06 Tx date 2019-08-08 |
$ASP
Acerus Pharmaceuticals Corporation |
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+429,225 vol |
429,225 | |
Filed 2019-08-12 10:04 Tx date 2019-05-31 |
$ASP
Acerus Pharmaceuticals Corporation |
Damstra, Gavin Julian Roberts
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2019-08-09 16:01 Tx date 2019-08-08 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,860
+40,500 vol $0.12 each |
129,000 | |
Filed 2019-08-09 15:56 Tx date 2019-08-08 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+324,826 vol |
1,074,826 | |
Filed 2019-08-09 15:49 Tx date 2019-08-08 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+249,420 vol |
1,474,692 | |
Filed 2019-03-29 Tx date 2019-03-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$1,000,000
+5,128,206 vol $0.195 each |
10,341,706 | |
Filed 2019-03-29 Tx date 2019-03-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$3,000,000
+15,384,616 vol $0.195 each |
117,903,400 | |
Filed 2019-03-29 Tx date 2019-03-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$500,000
+2,564,103 vol $0.195 each |
4,558,730 | |
Filed 2019-03-29 Tx date 2019-03-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$30,000
+153,847 vol $0.195 each |
263,847 | |
Filed 2019-03-07 Tx date 2019-03-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,000
+200,000 vol $0.13 each |
600,000 | |
Filed 2019-03-07 Tx date 2019-03-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
$26,000
+200,000 vol $0.13 each |
675,000 | |
Filed 2019-03-07 Tx date 2019-03-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,000
+200,000 vol $0.13 each |
400,000 | |
Filed 2019-03-07 Tx date 2019-03-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,000
+200,000 vol $0.13 each |
600,000 | |
Filed 2019-03-07 Tx date 2019-03-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,000
+200,000 vol $0.13 each |
725,000 | |
Filed 2018-12-28 Tx date 2018-12-27 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,135
+28,500 vol $0.11 each |
88,500 | |
Filed 2018-12-26 Tx date 2018-12-24 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$49,463
+429,000 vol $0.1153 each |
1,994,627 | |
Filed 2018-12-20 Tx date 2018-12-20 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,990
+100,000 vol $0.1199 each |
5,213,500 | |
Filed 2018-12-17 Tx date 2018-12-17 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$29,315
+225,500 vol $0.13 each |
5,113,500 | |
Filed 2018-12-11 Tx date 2018-12-10 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,632
+19,500 vol $0.135 each |
1,535,127 | |
Filed 2018-12-11 Tx date 2018-12-11 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,117
+30,500 vol $0.135 each |
1,565,627 | |
Filed 2018-12-07 Tx date 2018-12-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$43,200
+320,000 vol $0.135 each |
1,515,627 | |
Filed 2018-12-07 Tx date 2018-12-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,917
+14,200 vol $0.135 each |
47,200 | |
Filed 2018-11-30 Tx date 2018-11-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,320
+14,500 vol $0.16 each |
109,500 | |
Filed 2018-11-30 Tx date 2018-11-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$77.50
+500 vol $0.155 each |
110,000 | |
Filed 2018-11-21 Tx date 2018-11-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,800
+10,000 vol $0.18 each |
95,000 | |
Filed 2018-11-20 Tx date 2018-11-20 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,600
+10,000 vol $0.16 each |
85,000 | |
Filed 2018-11-19 Tx date 2018-11-19 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,750
+75,000 vol $0.17 each |
75,000 | |
Filed 2018-11-19 Tx date 2018-10-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-19 Tx date 2018-10-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-19 Tx date 2018-11-19 |
$ASP
Acerus Pharmaceuticals Corporation |
Motz, Robert Martin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+750,000 vol |
750,000 | |
Filed 2018-09-11 Tx date 2018-09-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,760
+24,000 vol $0.24 each |
1,101,627 | |
Filed 2018-09-11 Tx date 2018-09-10 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$22,560
+94,000 vol $0.24 each |
1,195,627 | |
Filed 2018-09-07 Tx date 2018-09-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,640
+14,000 vol $0.26 each |
40,000 | |
Filed 2018-08-31 Tx date 2018-08-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$560.00
+2,000 vol $0.28 each |
6,000 | |
Filed 2018-08-31 Tx date 2018-08-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,600
+20,000 vol $0.28 each |
26,000 | |
Filed 2018-08-29 Tx date 2018-08-28 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$115,199
+400,000 vol $0.288 each |
4,888,000 | |
Filed 2018-08-29 Tx date 2017-12-06 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-29 Tx date 2018-08-28 |
$ASP
Acerus Pharmaceuticals Corporation |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,120
+4,000 vol $0.28 each |
4,000 | |
Filed 2018-08-28 Tx date 2018-08-24 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$49,035
+175,000 vol $0.2802 each |
4,264,000 | |
Filed 2018-08-28 Tx date 2018-08-28 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,600
+20,000 vol $0.28 each |
60,000 | |
Filed 2018-08-28 Tx date 2018-08-27 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$62,720
+224,000 vol $0.28 each |
4,488,000 | |
Filed 2018-08-24 Tx date 2018-08-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$80,621
+281,500 vol $0.2864 each |
4,089,000 | |
Filed 2018-08-24 Tx date 2018-08-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$125,222
+445,000 vol $0.2814 each |
2,561,000 | |
Filed 2018-08-24 Tx date 2018-08-22 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$142,545
+496,500 vol $0.2871 each |
3,807,500 | |
Filed 2018-08-24 Tx date 2018-08-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$217,499
+750,000 vol $0.29 each |
3,311,000 | |
Filed 2018-08-24 Tx date 2018-08-20 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$50,187
+186,500 vol $0.2691 each |
2,116,000 | |
Filed 2018-08-22 Tx date 2018-08-21 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,080
+42,000 vol $0.24 each |
1,077,627 | |
Filed 2018-08-20 Tx date 2018-08-15 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,000,000 vol |
1,000,000 | |
Filed 2018-08-20 Tx date 2018-08-17 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$215,690
+769,500 vol $0.2803 each |
1,929,500 | |
Filed 2018-08-20 Tx date 2018-08-15 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$38,720
+176,000 vol $0.22 each |
176,000 | |
Filed 2018-08-20 Tx date 2018-05-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-20 Tx date 2018-08-17 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,450
+35,000 vol $0.27 each |
1,035,627 | |
Filed 2018-08-20 Tx date 2018-05-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-20 Tx date 2018-08-16 |
$ASP
Acerus Pharmaceuticals Corporation |
Gudaitis, Edward Joseph
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$230,157
+984,000 vol $0.2339 each |
1,160,000 | |
Filed 2018-08-15 Tx date 2018-08-15 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$15,840
+72,000 vol $0.22 each |
559,900 | |
Filed 2018-08-15 Tx date 2018-08-15 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,880
+28,000 vol $0.21 each |
487,900 | |
Filed 2018-05-17 Tx date 2015-12-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-05-17 Tx date 2015-12-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-05-17 Tx date 2015-12-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
57,500 | ||
Filed 2018-05-17 Tx date 2015-12-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$81.00
+300 vol $0.27 each |
26,800 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+316,598 vol |
1,316,598 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$20,412
+72,900 vol $0.28 each |
459,900 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,287
+26,500 vol $0.275 each |
26,500 | |
Filed 2018-03-26 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RRSP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+334,863 vol |
1,634,863 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+225,272 vol |
1,225,272 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
1,175,000 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
1,075,000 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
475,000 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
525,000 | |
Filed 2018-03-26 Tx date 2018-03-22 |
$ASP
Acerus Pharmaceuticals Corporation |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$99,184
+374,000 vol $0.2652 each |
1,000,627 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
400,000 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+316,598 vol |
2,701,598 | |
Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
400,000 | |
Filed 2018-03-21 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
300,000 | |
Filed 2017-12-27 Tx date 2017-12-27 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$14,324
+50,000 vol $0.2865 each |
3,002,100 | |
Filed 2017-12-27 Tx date 2017-12-27 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,339
+27,900 vol $0.2989 each |
3,030,000 | |
Filed 2017-12-21 Tx date 2017-12-18 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$14,910
+49,700 vol $0.30 each |
49,700 | |
Filed 2017-12-21 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Holder: Sera Kim RESP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-12-11 Tx date 2017-12-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-12-11 Tx date 2017-12-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$72,000
+200,000 vol $0.36 each |
200,000 | |
Filed 2017-12-01 Tx date 2017-11-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$29,202
+157,000 vol $0.186 each |
1,213,500 | |
Filed 2017-12-01 Tx date 2017-11-27 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$40,929
+194,900 vol $0.21 each |
1,426,400 | |
Filed 2017-12-01 Tx date 2017-11-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,200
+16,000 vol $0.20 each |
1,231,500 | |
Filed 2017-12-01 Tx date 2017-11-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$390.00
+2,000 vol $0.195 each |
1,215,500 | |
Filed 2017-12-01 Tx date 2017-11-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$20,760
+120,000 vol $0.173 each |
1,056,500 | |
Filed 2017-12-01 Tx date 2017-11-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,845
+28,500 vol $0.17 each |
936,500 | |
Filed 2017-11-21 Tx date 2017-11-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,440
+32,000 vol $0.17 each |
191,000 | |
Filed 2017-11-21 Tx date 2017-11-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$33,320
+196,000 vol $0.17 each |
387,000 | |
Filed 2017-11-20 Tx date 2017-11-17 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$918.00
+5,100 vol $0.18 each |
2,952,100 | |
Filed 2017-11-20 Tx date 2017-11-15 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$300.00
+2,000 vol $0.15 each |
2,947,000 | |
Filed 2017-11-17 Tx date 2017-11-14 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,812
+12,500 vol $0.145 each |
149,500 | |
Filed 2017-11-17 Tx date 2017-11-15 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,330
+9,500 vol $0.14 each |
159,000 | |
Filed 2017-11-17 Tx date 2017-11-13 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,680
+62,000 vol $0.14 each |
137,000 | |
Filed 2017-11-15 Tx date 2016-07-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-11-15 Tx date 2017-11-15 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,950
+33,000 vol $0.15 each |
33,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$62,500
+500,000 vol $0.125 each |
2,695,000 | |
Filed 2017-11-13 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
1,300,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
1,000,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,750
+75,000 vol $0.13 each |
75,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
1,000,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$24,000
+200,000 vol $0.12 each |
1,000,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
800,000 | |
Filed 2017-11-13 Tx date 2017-11-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,095
+97,000 vol $0.135 each |
2,945,000 | |
Filed 2017-11-13 Tx date 2017-11-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$18,135
+139,500 vol $0.13 each |
2,848,000 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,620
+13,500 vol $0.12 each |
2,708,500 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
2,385,000 | |
Filed 2017-09-01 Tx date 2017-08-28 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$30,245
+263,000 vol $0.115 each |
908,000 | |
Filed 2017-06-06 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
500,000 | |
Filed 2017-06-06 Tx date 2017-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Yoon, Kae-Won
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-06-02 Tx date 2017-06-02 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,680
+39,000 vol $0.12 each |
424,500 | |
Filed 2017-05-24 Tx date 2017-05-17 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+900,000 vol |
8,048,325 | |
Filed 2017-03-24 Tx date 2017-03-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,782
+15,500 vol $0.115 each |
512,127 | |
Filed 2017-03-24 Tx date 2017-03-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,127
+18,500 vol $0.115 each |
626,627 | |
Filed 2017-03-24 Tx date 2017-03-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,040
+96,000 vol $0.115 each |
608,127 | |
Filed 2017-03-14 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
300,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
500,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
800,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,000
+100,000 vol $0.11 each |
385,500 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
1,885,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
425,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
375,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
300,000 | |
Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+2,000,000 vol |
7,148,325 | |
Filed 2016-12-08 Tx date 2016-12-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,875
+95,000 vol $0.125 each |
2,195,000 | |
Filed 2016-11-23 Tx date 2016-11-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$14,729
+100,000 vol $0.1473 each |
285,500 | |
Filed 2016-11-14 Tx date 2016-11-14 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,000
+100,000 vol $0.13 each |
2,100,000 | |
Filed 2016-11-08 Tx date 2016-11-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$90,000
+500,000 vol $0.18 each |
500,000 | |
Filed 2016-11-08 Tx date 2016-11-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Symmes, Tricia
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-11-04 Tx date 2016-11-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,550
+15,000 vol $0.17 each |
40,000 | |
Filed 2016-08-23 Tx date 2016-08-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+325,000 vol |
5,148,325 | |
Filed 2016-08-23 Tx date 2016-08-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,600
+60,000 vol $0.16 each |
185,500 | |
Filed 2016-08-22 Tx date 2016-08-19 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$49,000
+350,000 vol $0.14 each |
645,000 | |
Filed 2016-08-17 Tx date 2016-08-16 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$90,000
+1,000,000 vol $0.09 each |
2,000,000 | |
Filed 2016-08-12 Tx date 2016-08-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
300,000 | |
Filed 2016-08-12 Tx date 2016-07-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-12 Tx date 2016-08-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
100,000 | |
Filed 2016-08-12 Tx date 2016-07-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-08-12 Tx date 2016-08-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,250
+25,000 vol $0.09 each |
25,000 | |
Filed 2016-08-12 Tx date 2015-06-26 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-27 Tx date 2016-07-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,000,000 | ||
Filed 2016-06-22 Tx date 2016-06-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,080
+16,000 vol $0.13 each |
291,000 | |
Filed 2016-06-22 Tx date 2016-06-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$12,900
+100,000 vol $0.129 each |
275,000 | |
Filed 2016-06-22 Tx date 2016-06-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,800
+60,000 vol $0.13 each |
125,500 | |
Filed 2016-06-10 Tx date 2016-06-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-175,603.80
-1,463,365 vol $0.12 each |
20,913,418 | |
Filed 2016-06-10 Tx date 2016-06-08 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-40,560
-312,000 vol $0.13 each |
22,376,783 | |
Filed 2016-06-10 Tx date 2016-06-08 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,000
-88,000 vol $0.125 each |
22,688,783 | |
Filed 2016-06-10 Tx date 2016-06-07 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-202.50
-1,500 vol $0.135 each |
22,776,783 | |
Filed 2016-06-10 Tx date 2016-06-07 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-47,645
-366,500 vol $0.13 each |
22,778,283 | |
Filed 2016-06-10 Tx date 2016-06-03 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,417.50
-10,500 vol $0.135 each |
23,144,783 | |
Filed 2016-06-10 Tx date 2016-06-03 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,622
-20,000 vol $0.1311 each |
23,155,283 | |
Filed 2016-06-10 Tx date 2016-06-03 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,260
-202,000 vol $0.13 each |
23,175,283 | |
Filed 2016-06-10 Tx date 2016-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-13,702.50
-101,500 vol $0.135 each |
23,377,283 | |
Filed 2016-06-10 Tx date 2016-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-25,225.10
-193,000 vol $0.1307 each |
23,478,783 | |
Filed 2016-06-10 Tx date 2016-06-01 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,715
-205,500 vol $0.13 each |
23,671,783 | |
Filed 2016-06-10 Tx date 2016-05-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-652.50
-4,500 vol $0.145 each |
23,877,283 | |
Filed 2016-06-10 Tx date 2016-05-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-22,680
-162,000 vol $0.14 each |
23,881,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,100
-14,000 vol $0.15 each |
24,043,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,160
-8,000 vol $0.145 each |
24,057,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-25,311
-177,000 vol $0.143 each |
24,065,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,100
-115,000 vol $0.14 each |
24,242,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,808
-28,000 vol $0.136 each |
24,357,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,345
-47,000 vol $0.135 each |
24,385,783 | |
Filed 2016-06-10 Tx date 2016-05-25 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-14,430
-111,000 vol $0.13 each |
24,432,783 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,520
-9,500 vol $0.16 each |
24,543,783 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,340
-15,000 vol $0.156 each |
24,553,283 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-17,592.50
-113,500 vol $0.155 each |
24,568,283 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-17,475
-116,500 vol $0.15 each |
24,681,783 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,047.50
-55,500 vol $0.145 each |
24,798,283 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-5,760
-40,000 vol $0.144 each |
24,853,783 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-10,850
-77,500 vol $0.14 each |
24,893,783 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-810.00
-6,000 vol $0.135 each |
24,971,283 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,620
-20,000 vol $0.131 each |
24,977,283 | |
Filed 2016-06-10 Tx date 2016-05-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,690
-13,000 vol $0.13 each |
24,997,283 | |
Filed 2016-06-10 Tx date 2016-05-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,275
-105,000 vol $0.155 each |
25,010,283 | |
Filed 2016-06-10 Tx date 2016-05-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-43,650
-291,000 vol $0.15 each |
25,115,283 | |
Filed 2016-06-10 Tx date 2016-05-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-59,914.80
-396,000 vol $0.1513 each |
||
Filed 2016-06-10 Tx date 2016-05-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-59,914.80
-396,000 vol $0.1513 each |
||
Filed 2016-06-10 Tx date 2016-05-19 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,471.50
-149,500 vol $0.157 each |
25,406,283 | |
Filed 2016-06-10 Tx date 2016-05-19 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,650
-10,000 vol $0.165 each |
25,555,783 | |
Filed 2016-06-10 Tx date 2016-05-19 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-12,880
-80,500 vol $0.16 each |
25,565,783 | |
Filed 2016-06-10 Tx date 2016-05-19 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,547.50
-74,500 vol $0.155 each |
25,646,283 | |
Filed 2016-06-10 Tx date 2016-05-19 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-27,825
-185,500 vol $0.15 each |
25,720,783 | |
Filed 2016-06-10 Tx date 2016-05-16 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,840
-52,000 vol $0.17 each |
25,906,283 | |
Filed 2016-06-10 Tx date 2016-05-16 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-47,025
-285,000 vol $0.165 each |
25,958,283 | |
Filed 2016-06-10 Tx date 2016-05-16 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,080
-113,000 vol $0.16 each |
26,243,283 | |
Filed 2016-06-10 Tx date 2016-05-16 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,750
-50,000 vol $0.155 each |
26,356,283 | |
Filed 2016-06-10 Tx date 2016-05-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-10,725
-65,000 vol $0.165 each |
26,406,283 | |
Filed 2016-06-10 Tx date 2016-05-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,920
-12,000 vol $0.16 each |
26,471,283 | |
Filed 2016-06-10 Tx date 2016-05-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,635
-17,000 vol $0.155 each |
26,483,283 | |
Filed 2016-06-10 Tx date 2016-05-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,425
-109,500 vol $0.15 each |
26,500,283 | |
Filed 2016-06-10 Tx date 2016-05-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-22,620
-156,000 vol $0.145 each |
26,609,783 | |
Filed 2016-06-10 Tx date 2016-05-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,635
-15,500 vol $0.17 each |
26,765,783 | |
Filed 2016-06-10 Tx date 2016-05-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,630
-22,000 vol $0.165 each |
26,781,283 | |
Filed 2016-06-10 Tx date 2016-05-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-20,480
-128,000 vol $0.16 each |
26,803,283 | |
Filed 2016-06-10 Tx date 2016-05-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-12,400
-80,000 vol $0.155 each |
26,931,283 | |
Filed 2016-06-10 Tx date 2016-05-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-47,550
-317,000 vol $0.15 each |
27,011,283 | |
Filed 2016-06-10 Tx date 2016-03-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-701.25
-8,500 vol $0.0825 each |
||
Filed 2016-06-10 Tx date 2016-03-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-701.25
-8,500 vol $0.0825 each |
||
Filed 2016-06-10 Tx date 2016-03-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-54,280
-678,500 vol $0.08 each |
||
Filed 2016-06-10 Tx date 2016-03-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-54,280
-678,500 vol $0.08 each |
||
Filed 2016-06-10 Tx date 2016-03-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,330
-14,000 vol $0.095 each |
27,328,283 | |
Filed 2016-06-10 Tx date 2016-03-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,830
-187,000 vol $0.09 each |
27,342,283 | |
Filed 2016-06-10 Tx date 2016-03-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,925
-22,000 vol $0.0875 each |
27,529,283 | |
Filed 2016-06-10 Tx date 2016-03-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,650
-90,000 vol $0.085 each |
27,551,283 | |
Filed 2016-06-10 Tx date 2016-03-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-701.25
-8,500 vol $0.0825 each |
27,641,283 | |
Filed 2016-06-10 Tx date 2016-03-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-54,280
-678,500 vol $0.08 each |
27,649,783 | |
Filed 2016-06-10 Tx date 2016-03-17 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,455
-89,000 vol $0.095 each |
28,328,283 | |
Filed 2016-06-10 Tx date 2016-03-17 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-24,795
-275,500 vol $0.09 each |
28,417,283 | |
Filed 2016-06-10 Tx date 2016-03-17 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-19,975
-235,000 vol $0.085 each |
28,692,783 | |
Filed 2016-06-10 Tx date 2016-03-17 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,040
-400,500 vol $0.08 each |
28,927,783 | |
Filed 2016-05-18 Tx date 2016-05-13 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,246,388
+51,437,691 vol $0.1992 each |
102,518,784 | |
Filed 2016-05-17 Tx date 2016-05-13 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-36,979,391 vol |
0 | |
Filed 2016-03-31 Tx date 2016-03-28 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,400
+74,000 vol $0.10 each |
51,081,093 | |
Filed 2016-03-31 Tx date 2016-03-28 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$368,000
+2,944,000 vol $0.125 each |
51,007,093 | |
Filed 2016-03-31 Tx date 2016-03-28 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$31,780
+227,000 vol $0.14 each |
496,627 | |
Filed 2016-03-31 Tx date 2016-03-28 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,690
+13,000 vol $0.13 each |
269,627 | |
Filed 2016-03-31 Tx date 2016-03-28 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Holder: 8197288 Canada Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,200
+10,000 vol $0.12 each |
256,627 | |
Filed 2016-03-30 Tx date 2016-03-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,500
+45,000 vol $0.10 each |
65,500 | |
Filed 2016-03-28 Tx date 2016-03-24 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$25,840
+272,000 vol $0.095 each |
48,063,093 | |
Filed 2016-03-28 Tx date 2016-03-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Holder: First Generation Capital Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$17,010
+189,000 vol $0.09 each |
47,791,093 | |
Filed 2016-03-09 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$10,000
+100,000 vol $0.10 each |
100,000 | |
Filed 2016-03-09 Tx date 2015-12-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Sherman, Jeffrey Dennis
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
225,000 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Rossi, Tom
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+2,000,000 vol |
4,823,325 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Reininghaus, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
1,392,500 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
154,865 | |
Filed 2016-03-08 Tx date 2015-12-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
54,865 | ||
Filed 2016-03-08 Tx date 2015-12-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Quintyne, Arlene
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
12,500 | ||
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Ihnatowycz, Ian Orest
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
175,000 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Hawkins, Matthew
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+950,000 vol |
1,585,000 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
225,000 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
100,000 | |
Filed 2016-03-08 Tx date 2015-12-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bumby, Michael Scott
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+400,000 vol |
600,000 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+950,000 vol |
1,285,000 | |
Filed 2016-03-08 Tx date 2016-03-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
100,000 | |
Filed 2016-03-08 Tx date 2015-06-26 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Beauchamp, Norma
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-01-08 Tx date 2016-01-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,080
-13,000 vol $0.16 each |
29,328,283 | |
Filed 2016-01-08 Tx date 2016-01-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,510
-42,000 vol $0.155 each |
29,341,283 | |
Filed 2016-01-08 Tx date 2016-01-06 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-29,250
-195,000 vol $0.15 each |
29,383,283 | |
Filed 2016-01-08 Tx date 2016-01-05 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-5,130
-28,500 vol $0.18 each |
29,578,283 | |
Filed 2016-01-08 Tx date 2016-01-05 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-262.50
-1,500 vol $0.175 each |
29,606,783 | |
Filed 2016-01-08 Tx date 2016-01-05 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,590
-27,000 vol $0.17 each |
29,608,283 | |
Filed 2016-01-08 Tx date 2016-01-05 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,440
-71,500 vol $0.16 each |
29,635,283 | |
Filed 2016-01-08 Tx date 2016-01-05 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,705
-11,000 vol $0.155 each |
29,706,783 | |
Filed 2016-01-08 Tx date 2016-01-05 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Melnyk, Eugene
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-16,575
-110,500 vol $0.15 each |
29,717,783 | |
Filed 2016-01-04 Tx date 2015-12-31 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-62,400
-520,000 vol $0.12 each |
36,979,391 | |
Filed 2016-01-03 Tx date 2015-12-30 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-40,152
-280,000 vol $0.1434 each |
37,499,391 | |
Filed 2015-12-30 Tx date 2015-12-29 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-28,940
-200,000 vol $0.1447 each |
37,779,391 | |
Filed 2015-12-29 Tx date 2015-12-29 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,200
+28,000 vol $0.15 each |
295,000 | |
Filed 2015-12-29 Tx date 2015-12-29 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,739
+12,000 vol $0.145 each |
267,000 | |
Filed 2015-12-29 Tx date 2015-12-22 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,900
+85,000 vol $0.14 each |
255,000 | |
Filed 2015-12-29 Tx date 2015-12-22 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$16,675
+115,000 vol $0.145 each |
170,000 | |
Filed 2015-12-25 Tx date 2015-12-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Vejvoda, Josef
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
230,000 | ||
Filed 2015-12-23 Tx date 2015-12-20 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Chabursky, Borys
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
57,500 | ||
Filed 2015-12-23 Tx date 2015-12-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,575
+9,000 vol $0.175 each |
20,500 | |
Filed 2015-12-23 Tx date 2015-12-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Bryson, Nathan John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,190
+7,000 vol $0.17 each |
11,500 | |
Filed 2015-12-21 Tx date 2015-12-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
West Face Capital Inc.
3 - 10% Security Holder of Issuer
Holder: West Face Long Term Opportunities Global Master L.P. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
37,979,391 | ||
Filed 2015-09-24 Tx date 2015-09-22 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Pfeffer, Matthew Jonathan
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,000
+20,000 vol $0.40 each |
20,000 | |
Filed 2015-09-24 Tx date 2013-11-27 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Pfeffer, Matthew Jonathan
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-09-24 Tx date 2015-09-23 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,000
+20,000 vol $0.40 each |
55,000 | |
Filed 2015-09-24 Tx date 2015-09-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,905
+7,000 vol $0.415 each |
35,000 | |
Filed 2015-09-24 Tx date 2015-09-21 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Gregory, Stephen Robert
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,260
+3,000 vol $0.42 each |
28,000 |